Novartis Phase III Trials Show Ianalumab Significantly Improves Outcomes in Sjögren’s Disease

Ianalumab Meets Primary End Points in Phase 3 NEPTUNUS Trials of Sjögren’s Disease

Novartis revealed promising phase 3 trial results for ianalumab, a potential first treatment for Sjögren’s disease, showing significant disease activity reduction.

Novartis’ Sjögren's, Thrombocytopenia Drug Performs Well at Phase III

A monoclonal antibody drug, ianalumab, developed by Novartis to treat B-cell driven diseases has succeeded in significantly reducing symptoms of Sjögren’s disease in two Phase III trials. The big pharma also tested the same drug for treatment of primary immune thrombocytopenia (ITP) in another Phase III trial in combination with a thrombocytopenia drug eltrombopag and the results of that trial were also positive. Ianalumab was originally develop…

Novartis’ mAb could become first Sjögren’s disease drug after Phase III success

If approved, Novartis' ianalumab would become the first targeted treatment for patients with Sjögren’s disease.The post Novartis’ mAb could become first Sjögren’s disease drug after Phase III success appeared first on Clinical Trials Arena.

Novartis Phase III Trials Show Ianalumab Significantly Improves Outcomes in Sjögren’s Disease

Open the article to view the coverage from EuropaWire.eu

Expro delivers remote five-plug cementing operation, Saudi Arabia - Drilling Contractor

Expro delivered the first fully remote five-plug cementing operation in the Kingdom of Saudi Arabia. Expro’s Generation-X Remote Plug Launcher (RPL) and proprietary SkyHook cement-line make-up device enabled a complex, multi-stage cement job to be completed with zero red-zone entry or man-riding operations. The five-plug stage-cementing operation was executed for a challenging 9-5/8” casing run … The post Expro delivers remote five-plug cementin…